UpdatesPlus - Immunology

Description

Source URL:

https://lapix.com/press_release/lapix-therapeutics-inc-announces-first-subjects-dosed-in-its-first-in-human-clinical-study-of-its-treg-expanding-tim3-4-agonist-lpx-ti641-to-treat-multiple-sclerosis-and-other-autoimmune-conditions/